

STATEMENT OF AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2023 & UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR QUARTER ENDED 31st MARCH, 2023.

Rs.in Lakhs

Sl. No.	PARTICULARS	STANDALONE				
		For the Quarter Ended			For the Year Ended	
		31-03-2023 UN-AUDITED	31/12/2022 UN-AUDITED	31-03-2022 UN-AUDITED	31-03-2023 AUDITED	31/03/2022 AUDITED
1	Income					
	Revenue from operations	36,438.99	34,848.90	36,384.72	1,33,007.98	1,32,022.21
	Other Income	1,075.46	1,251.05	13,439.58	4,455.20	18,778.80
	Total income	37,514.45	36,099.95	49,824.30	1,37,463.18	1,50,801.01
2	Expenses					
	a) Cost of materials consumed	8,956.75	13,516.42	13,027.81	42,136.24	45,945.64
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,087.68	(2,650.99)	(1,994.03)	(2,094.42)	(6,035.21)
	c) Manufacturing Expenses	3,899.88	4,599.26	4,434.34	17,087.35	17,318.86
	d) Employee benefits expense	2,289.99	2,726.37	3,112.20	10,084.31	10,048.39
	e) R & D expense	200.89	226.99	214.42	858.57	1,035.45
	f) Finance costs	228.95	137.94	218.87	539.17	623.10
	g) Depreciation and amortisation expenses	1,062.73	1,091.38	1,042.08	4,284.46	3,909.71
	h) Other Expenses	1,540.99	1,724.14	1,833.11	6,628.17	5,710.25
	Total expenses	20,267.86	21,371.51	21,888.80	79,523.85	78,556.19
3	Profit before exceptional items & Tax (1-2)	17,246.59	14,728.44	27,935.50	57,939.33	72,244.82
4	Exceptional Items	-	-	-	-	-
5	Profit before Tax (3-4)	17,246.59	14,728.44	27,935.50	57,939.33	72,244.82
6	Tax Expenses					
	a) Current tax	4,296.76	3,715.23	5,148.01	14,462.56	15,763.03
	b) Deferred tax	150.88	66.59	341.02	433.75	671.91
	c) Prior year tax	(217.23)	-	-	(217.23)	-
7	Net Profit/ (Loss) for the period/ year (5-6)	13,016.18	10,946.62	22,446.47	43,260.25	55,809.88
8	Other Comprehensive Income					
8.a	(i) Items that will not be reclassified to profit or loss	41.29	(25.48)	(18.06)	(35.16)	(101.95)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(10.39)	6.41	4.55	8.85	25.66
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income	30.90	(19.07)	(13.51)	(26.31)	(76.29)
9	Total Comprehensive Income for the period (7+8)	13,047.08	10,927.55	22,432.96	43,233.94	55,733.59
10	Paid-up equity share capital Face Value of the Share	2,545.65 Re. 1.00	2,545.65 Re. 1.00	2,545.65 Re. 1.00	2,545.65 Re. 1.00	2,545.65 Re. 1.00
11	Other Equity				1,72,392.41	1,49,523.67
12	Earning Per Share (EPS)-Face value of Rs. 1/- each)					
	a) Basic	5.11	4.30	8.82	16.99	21.92
	b) Diluted	5.11	4.30	8.82	16.99	21.92
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)

		CONSOLIDATED				
Sl. No.	PARTICULARS	For the Quarter Ended			For the Year Ended	
		31-03-2023	31/12/2022	31-03-2022	31-03-2023	31/03/2022
		UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED	AUDITED
1	Income					
	Revenue from operations	36,935.62	35,377.17	36,384.72	1,34,032.88	1,32,022.21
	Other Income	1,139.95	1,301.12	1,687.12	4,636.38	9,238.03
	Total income	38,075.57	36,678.29	38,071.84	1,38,669.26	1,41,260.24
2	Expenses					
	a) Cost of materials consumed	9,555.70	13,603.62	13,027.81	43,007.88	45,945.64
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,087.69	(2,639.91)	(1,994.03)	(2,094.42)	(6,035.21)
	c) Manufacturing Expenses	4,046.62	4,736.40	4,434.34	17,628.79	17,318.86
	d) Employee benefits expense	2,560.21	2,967.54	3,112.20	11,051.09	10,048.39
	e) R & D expense	200.90	226.98	214.42	858.57	1,035.45
	f) Finance costs	230.86	138.27	218.87	543.63	623.10
	g) Depreciation and amortisation expense	1,195.83	1,223.90	1,042.08	4,773.24	3,909.71
	h) Other Expenses	1,576.67	1,813.06	1,887.94	6,927.50	5,766.55
	Total expenses	21,454.48	22,069.86	21,943.63	82,696.28	78,612.49
3	Profit before exceptional items, Tax & share in profit/(Loss) of Associates (1-2)	16,621.09	14,608.43	16,128.21	55,972.98	62,647.75
4	Add : Share of profit/(Loss) of Associates.	-	-	-	-	4,111.23
5	Profit before exceptional items , Tax (3+4)	16,621.09	14,608.43	16,128.21	55,972.98	66,758.98
6	Exceptional Items	-	-	-	-	-
7	Profit before Tax (5-6)	16,621.09	14,608.43	16,128.21	55,972.98	66,758.98
8	Tax Expenses					
	a) Current tax	4,290.32	3,769.77	5,964.54	14,627.43	19,040.47
	b) Deferred tax	150.87	66.60	996.87	433.75	2,338.02
	c) Prior year tax	(217.23)			(217.23)	
9	Net Profit/ (Loss) for the period/year(7-8)	12,397.13	10,772.06	9,166.80	41,129.03	45,380.49
10	Other Comprehensive Income					
10.a	(i) Items that will not be reclassified to profit or loss	49.28	(25.60)	(18.06)	(27.49)	(101.95)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(10.39)	6.41	4.55	8.85	25.66
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income	38.89	(19.19)	(13.51)	(18.64)	(76.29)
11	Total Comprehensive Income for the period (9 + 10)	12,436.02	10,752.87	9,153.29	41,110.39	45,304.20
12	Paid-up equity share capital Face Value of the Share	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00
13	Other Equity				1,70,972.78	1,50,172.39
14	Earning Per Share (EPS)- (Face value of Rs.1/- each)					
	a) Basic -	4.87	4.23	3.60	16.16	17.83
	b) Diluted	4.87	4.23	3.60	16.16	17.83
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)

- Notes**
- 1)** The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 25th May, 2023. The results for the year ended 31st March, 2023 have been audited and for the quarter ended 31st March, 2023 has been reviewed by our statutory auditors. The statutory auditors of the company have expressed an unmodified opinion on the financials statements for the year ended 31st March, 2023 and issued an unmodified conclusion in respect of limited review for the quarter ended 31st March, 2023.
 - 2)** The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
 - 3)** The consolidated financial results include the results of the wholly owned subsidiaries Suven Pharma, Inc., USA & Casper Pharma Pvt Ltd, (w.e.f. 22nd April '2022).
 - 4)** The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
 - 5)** The other Income (Standalone figures for the year-2021-22 includes an amount of Rs.15081.85 Lacs (Q2 Rs.3329.39 lacs & Q4 Rs.11752.46 lacs) pertaining to the Dividends received and Rs.1080.41 lacs (Q4) pertaining to Gain on Investments on part disinvestment of Capital from our Wholly Owned Subsidiary, Suven Pharma, Inc. The Current tax for the year 2021-22 (Standalone figures) includes an amount of Rs.1676.21 lacs (Q3 Rs.491.72 Lacs & Q4 Rs.1184.49 Lacs) withholding tax paid on such dividend by our wholly owned subsidiary.
 - 6)** The Suven Pharma Inc., the WOS of our Company has divested it's entire stake (25% amounting to \$35.00 Mn) in M/s Rising pharma Holdings, Inc., USA on 13th Dec, 2021 to Raisin Acquisition Co, Inc., one of the investment arms of H.I.G. Capital, USA through structured deal. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of US \$41.555 Mn and a stake valued at US \$15.803 Mn in Raisin Aggregators, L.P. Accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company w.e.f 13th Dec'2021
 - 7)** Post approval of the Board in the meeting held on 5th April 2022, the company has completed acquisition of 100% stake in Casper Pharma Pvt Ltd, (SEZ company) engaged in formulations business for US \$20.50 Mn and has become a Wholly Owned Subsidiary of the Company w.e.f 22 nd April 2022. Subsequently subscribed the right issue in the ratio of 1:4 on 22/06/2022 of 52,16,156 shares of face value of Rs.10.00 with a premium of Rs.70.00 per share for Rs.4172.92 Lacs.
 - 8)** The Promoter Group, Jasti Property and Equity Holdings Private Limited (in their capacity as sole trustee of Jasti Family Trust), informed the Company that they executed a Share Purchase Agreement to sell 12,75,37,043 Equity shares representing 50.10% of the Voting share capital to Berhyanda Limited company on 26th December 2022.
 - 9)** The corresponding previous period figures have been regrouped/reclassified where ever necessary.

For SUVEN PHARMACEUTICALS LTD

Place : Hyderabad
Date : 25th May ' 2023

VENKATESWARLU JASTI
Managing Director
DIN: 00278028



SUVEN PHARMACEUTICALS LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

Statement of Assets & Liabilities

Rs.in Lakhs

Particulars	Standalone as at		Consolidated as at	
	31/03/2023	31-03-2022	31/03/2023	31-03-2022
A ASSETS	Audited	Audited	Audited	Audited
1 Non-current assets				
(a) Property, Plant and Equipment	50,900.87	53,055.18	58,418.83	53,055.18
(b) Capital Work-in-Progress	16,481.46	2,999.38	16,508.86	2,999.38
(c) Other Intangible Assets	193.20	223.64	6,219.02	223.64
(e) Right of use of assets	108.67	140.56	1,694.80	140.56
(f) Financial Assets				
I. Investments	31,721.01	11,867.29	11,709.66	11,709.67
II. Loans	2.25	6.95	2.25	6.95
III. Other Financial Assets	591.19	539.21	591.19	1,269.59
(g) Other non current assets	322.75	760.56	325.19	760.56
Total Non-Current assets	1,00,321.40	69,592.77	95,469.80	70,165.53
2 Current assets				
(a) Inventories	31,146.62	28,341.73	31,281.05	28,341.73
(b) Financial Assets				
I. Investments	39,284.94	48,122.24	41,893.50	48,122.24
II. Trade Receivables	10,966.45	23,637.23	11,093.93	23,637.23
III. Cash and Cash equivalents	4,302.13	3,021.05	6,480.28	4,456.38
IV. Bank balances other than (III) above	321.13	274.20	321.12	274.20
V. Loans	19.29	18.63	19.29	18.63
VI. Other financial Assets	28.17	-	28.17	-
(d) Other current assets	9,442.91	7,480.94	9,987.24	7,942.79
Total Current assets	95,511.64	1,10,896.02	1,01,104.58	1,12,793.20
TOTAL - ASSETS	1,95,833.04	1,80,488.79	1,96,574.38	1,82,958.73
B EQUITY AND LIABILITIES				
1 EQUITY				
(a) Equity Share Capital	2,545.65	2,545.65	2,545.65	2,545.65
(b) Other Equity	1,72,392.41	1,49,523.67	1,70,972.78	1,50,172.39
Equity attributable to owners of the company	1,74,938.06	1,52,069.32	1,73,518.43	1,52,718.04
2 LIABILITIES				
(a) Financial Liabilities				
I. Lease Liability	69.98	46.29	69.98	46.29
II. Borrowings	456.42	2,844.04	456.42	2,844.04
(b) Provisions	786.52	889.45	829.51	889.45
(c) Deferred tax Liabilities (net)	4,164.45	3,739.55	5,823.46	5,431.51
Total non-current liabilities	5,477.37	7,519.33	7,179.37	9,211.29
Current liabilities				
(a) Financial Liabilities				
I. Lease Liability	47.90	109.09	47.90	109.09
II. Borrowings	6,459.78	6,713.31	6,459.78	6,713.31
III. Trade payables				
a) To Micro & Small Enterprises	1,382.03	200.20	1,383.01	200.20
b) Other than Micro & Small Enterprises	4,814.35	10,389.85	5,133.42	10,389.85
IV. Other Financial Liabilities	2,015.35	2,126.01	2,133.20	2,255.27
(b) Current Tax liabilities (Net)	30.41	364.22	29.39	364.22
(c) Provisions	385.68	407.53	394.61	407.53
(d) Other Current liabilities	282.11	589.93	295.27	589.93
	15,417.61	20,900.14	15,876.58	21,029.40
Total Liabilities	20,894.98	28,419.47	23,055.95	30,240.69
TOTAL - EQUITY AND LIABILITIES	1,95,833.04	1,80,488.79	1,96,574.38	1,82,958.73

For Suven Pharmaceuticals Ltd

Place : Hyderabad
Date: 25th May, 2023Venkateswarlu Jasti
Managing Director

SUVEN PHARMACEUTICALS LIMITED			
Standalone Statement of Cash flows for the year ended 31st March, 2023			
(All amounts in Indian Rupees in Lakhs, unless otherwise stated)			
Particulars		For the year ended March 31, 2023	For the year ended March 31, 2022
A. Cash flow from operating activities			
Profit before tax		57939.33	72,244.82
Adjustments :			
Depreciation and amortisation expense		4190.40	3,825.50
Interest Income		(572.00)	(6.86)
Finance Cost		539.17	623.10
Gain on sale of Current Investment		(1421.05)	(820.31)
Dividend received from Subsidiary		0.00	(15,081.85)
Effects of foreign exchange rates (Unrealized)		95.43	442.01
Loss/(Profit) on disposal of Property, plant & equipment		0.65	(0.06)
Operating profit before working capital changes		60771.93	61226.35
Adjustments for (Increase)/decrease in operating assets			
Trade Receivables		12574.00	(13,608.80)
Inventories		(2804.89)	(8,233.69)
Other non current assets		31.89	26.97
Other current assets		(1962.11)	(621.56)
Adjustments for Increase/(decrease) in operating liabilities			
Trade Payables		(4392.64)	2,320.35
Long term provisions		(102.93)	224.85
Short term provision		(57.01)	44.86
Other financial liabilities		(754.26)	420.66
Other current liabilities		(307.82)	363.60
Cash generated from operating activities		62996.16	42163.59
Income taxes paid (net of refunds)		(14579.14)	(15,174.14)
Net Cash flows from operating activities	(A)	48417.02	26989.45
B. Cash flow from Investing activities			
Payments for Purchase of property, plant and equipment		(14460.65)	(7,518.67)
Proceeds from sale of Property, plant & equipment		7.20	0.06
Investment in Subsidiaries		(19853.72)	12,697.44
Dividend received from Subsidiary		0.00	15,081.85
Interest received from FD and debentures		572.00	6.86
Fixed deposits/margin money-placed/matured		(80.01)	(44.03)
Sale/(purchase) of mutual funds		10258.35	(29,242.55)
Bank balances not considered as cash and cash equivalents		(0.44)	(10.47)
Net cash flow from /(used in) investing activities	(B)	(23557.27)	(9,029.51)
C. Cash flows from financing activities			
(Repayment)/Proceeds from long term borrowings		(2375.75)	(960.48)
(Repayment)/Proceeds from short term borrowings		(261.05)	(3,856.56)
Changes in Lease Liabilities		(37.50)	(25.33)
Finance Cost		(539.17)	(623.10)
Dividends paid to equity holders (including dividend distribution tax)		(20365.20)	(10,182.60)
Net cash flow from /(used In) financing activities	(C)	(23578.67)	(15,648.07)
Net increase/(decrease) in cash and cash equivalents	(A+B+C)	1281.08	2311.87
Cash and cash equivalents as at the beginning of the year		3021.05	709.14
Effect of exchange differences on restatement on foreign currency cash & cash equivalents		0.00	0.04
Cash and cash equivalents at the end of the year		4302.13	3021.05
For Suvan Pharmaceuticals Ltd			
Venkateswarlu Jasti			
Managing Director			
DIN: 00278028			
Place : Hyderabad			
Date : 25th May 2023			

SUVEN PHARMACEUTICALS LIMITED			
Consolidated Statement of Cash flows for the year ended 31st March, 2023			
(All amounts in Indian Rupees in Lakhs, unless otherwise stated)			
Particulars		For the year ended March 31, 2023	For the year ended March 31, 2022
A. Cash flow from operating activities			
Profit before tax		55972.98	66,758.98
Adjustments :			
Depreciation and amortisation expense		4645.99	3,825.50
Interest Income		(583.16)	(6.86)
Finance Cost		543.63	623.10
Gain on sale of Current Investment		(1568.70)	(820.31)
Effects of foreign exchange rates (unrealized)		95.42	442.01
Loss/(Profit) on disposal of property, plant & equipment		0.65	(0.06)
Operating profit before working capital changes		59106.81	70822.36
Adjustments for (Increase)/decrease in operating assets			
Trade receivables		12446.52	(13,608.80)
Inventories		(2939.32)	(8,233.69)
Other non current assets		(1554.24)	26.97
Other current assets		(2044.58)	(1,083.41)
Adjustments for Increase/(decrease) in operating liabilities			
Trade payables		(4072.59)	2,320.35
Long term provisions		(59.94)	224.85
Short term provision		(40.41)	44.86
Other financial liabilities		(877.21)	548.66
Other current liabilities		(294.66)	363.60
Cash generated from operating activities		59670.38	51425.75
Income taxes paid (net of refunds)		(14579.14)	(18,425.73)
Net Cash flows from operating activities	(A)	45091.24	33000.02
B. Cash flow from Investing activities			
Purchase of property, plant and equipment		(28577.15)	(7,518.67)
Proceeds from sale of property, plant & equipment		7.20	0.06
Investment in subsidiaries		0.00	24,409.74
Interest received from FD and debentures		583.16	6.86
Foreign currency translation reserve		55.19	(484.39)
Fixed deposits/margin money-placed/matured		650.37	(774.41)
Sale/(purchase) of mutual funds		7797.44	(29,242.55)
Bank balances not considered as cash and cash equivalents		(0.44)	(10.47)
Net cash flow from /(used in) investing activities	(B)	(19484.22)	(13613.83)
C. Cash flows from financing activities			
(Repayment)/proceeds from long term borrowings		(2375.75)	(960.48)
(Repayment)/proceeds from short term borrowings		(261.05)	(3,856.56)
Changes in Lease Liabilities		(37.49)	(25.33)
Finance costs		(543.63)	(623.10)
Dividends paid to equity holders		(20365.20)	(10,182.60)
Net cash flow from /(used In) financing activities	(C)	(23583.12)	(15648.07)
Net increase/(decrease) in cash and cash equivalents	(A+B+C)	2023.90	3738.12
Cash and cash equivalents as at the beginning of the year		4456.38	718.22
Effect of exchange differences on restatement on foreign currency cash & cash equivalents		0.00	0.04
Cash and cash equivalents at the end of the year		6480.28	4456.38
For Suvan Pharmaceuticals Ltd			
Venkateswarlu Jasti			
Managing Director			
DIN: 00278028			
Place : Hyderabad			
Date : 25th May 2023			